mbeck

NMIN-Mitacs Intern developing novel cannabinoid delivery platforms

The NanoMedicines Innovation Network (NMIN) is pleased to announce the third recipient of an NMIN-Mitacs Internship. In an internship of one year’s duration, Dr. Farahnaz Fathordoobady, NMIN HQP and Postdoctoral Fellow at the University of British Columbia (UBC), will collaborate with Ascension Sciences Inc. (ASI) to develop a novel oral… Read More »NMIN-Mitacs Intern developing novel cannabinoid delivery platforms

Inaugural NMIN-Mitacs Internships at Cuprous Pharmaceuticals Inc.

The NanoMedicines Innovation Network (NMIN) is pleased to announce the inaugural recipients of NMIN-Mitacs Internships:  Drs. Kent Chen and Brian Hsu will both work with Cuprous Pharmaceuticals Inc. (CPI) on the development of novel nanomedicines to induce anticancer immunity, using CPI’s proprietary Metaplex technology. Dr. Kent Chen Dr. Brian Hsu… Read More »Inaugural NMIN-Mitacs Internships at Cuprous Pharmaceuticals Inc.

Lipid nanoparticle technology: poised to have a revolutionary impact

In a new review article published in Advanced Drug Delivery Reviews, NMIN researchers and colleagues discuss the use of state-of-the-art lipid nanoparticle (LNP) technology for therapeutic gene regulation in the liver. LNP technology enables the delivery of nucleic acids to treat liver diseases, addressing the root causes of these diseases… Read More »Lipid nanoparticle technology: poised to have a revolutionary impact

NMIN research leader discusses new diagnostic technology as key to “pandexit”

NMIN Research Leader Dr. Shana Kelley discusses how new rapid diagnostic technologies could transform the way the COVID-19 pandemic is managed, in a webinar recorded on July 7, 2020. https://youtu.be/Zj4-N_CyuRg In the video, Dr. Kelley discusses innovative technologies being developed by researchers in her multidisciplinary PRiME group, including NMIN researcher… Read More »NMIN research leader discusses new diagnostic technology as key to “pandexit”

Meet April O’Connell, NMIN’s new Manager, Research & Partnerships

As of July 13, 2020, NMIN has a new Manager of Research and Partnerships: April O’Connell, BA, CHRP, CHRL. April brings eight years’ experience managing a multimillion-dollar research portfolio for AllerGen NCE. April was nationally recognized in 2019 for excellence in research management by the Canadian Association of Research Administrators… Read More »Meet April O’Connell, NMIN’s new Manager, Research & Partnerships

NMIN researchers awarded CIHR funding for COVID-19 projects

Two NMIN researchers based at the University of British Columbia (UBC) have been awarded CIHR funding to support projects addressing COVID19-related health challenges. NMIN’s Scientific Director, Dr. Pieter Cullis, was awarded $237,445 in support of his effort to develop an antibody therapy for COVID-19. The project, seed-funded by NMIN, will… Read More »NMIN researchers awarded CIHR funding for COVID-19 projects

NMIN welcomes three new Board members

The NanoMedicines Innovation Network (NMIN) is pleased to welcome the following new members to its Board of Directors (L to R above): Vanessa Grant, Partner, Norton Rose Fulbright Canada LLP Inès Holzbaur, Co-Founder & Managing Partner, AmorChem David Martin, Managing Director & Head of Equity Research, Bloom Burton Securities “We… Read More »NMIN welcomes three new Board members

Meet NMIN’s HQP Program Advisory Committee (HPAC)

The NanoMedicines Innovation Network (NMIN) is pleased to introduce the inaugural members of its Highly Qualified Personnel (HQP) Program Advisory Committee (HPAC). The HQP Program Advisory Committee advises the Research Management Committee (RMC) of NMIN on training and programming opportunities that will increase the knowledge, skills and expertise of trainees… Read More »Meet NMIN’s HQP Program Advisory Committee (HPAC)